HealthcareAcousia Therapeutics to present its first-in-class hearing loss treatment...

Acousia Therapeutics to present its first-in-class hearing loss treatment program with ACOU085 at the 2nd Inner Ear Therapeutics Summit in Boston


Tübingen, Germany, May 11, 2022 Acousia Therapeutics GmbH will be presenting data on the company’s clinical stage, first-in-class lead candidate ACOU085 at the Hanson Wade 2nd Inner Ear Therapeutics Summit to be held in person in Boston (MA) from June 20–23, 2022.

ACOU085 is a proprietary, first-in-class, small-molecule otoprotective drug candidate, which is currently being tested in a Phase 1b clinical trial involving age-related hearing loss (ARHL) patients. Designed to modulate a biologically validated target – the KCNQ4-encoded Kv7.4 potassium channel, which is essential for maintaining auditory function – ACOU085 is being developed for the treatment and prevention of hearing loss for a number of acquired and inherited forms of sensorineural hearing loss.

ACOU085 is characterized by a unique dual mode of action, which provides acute functional enhancement and long-term protection for the terminally differentiated sensorineural outer hair cells. “Being invited to share the translational background and progress of our ACOU085 lead program with the hearing loss drug development community at the Inner Ear Therapeutics Summit is an exciting opportunity for us,” says Dr. Jonas Dyhrfjeld-Johnsen, Chief Development Officer at Acousia Therapeutics. “I look forward to stimulating discussions with our peers in Boston.”

In addition to receiving an invitation to present “Small Molecule, KCNQ4 Agonist ACOU085 for the Treatment and Prevention of Hearing Loss”, Dr. Dyhrfjeld-Johnsen will also participate as a panelist on the panel discussion “De-risking the Early Development Process: A Robust and Comprehensive Early Development Process Is Essential to Minimize Setbacks Faced in the Clinic” and in the workshop “Mind The Gap: Calling Out the Shortfalls in the Current Inner Ear Therapeutic Development Pathway and Illuminating Solutions”.

About Acousia Therapeutics
Acousia Therapeutics GmbH is a privately-held, clinical stage biotech company based in Tübingen, Germany. The company is dedicated to the identification and development of small molecules for effective prevention and treatment of different etiologies of hearing loss. Acousia Therapeutics develops drugs for local and systemic administration.

Contact
Tim Boelke, M.D.
boelke@acousia.com
+49 70712988186‬
www.acousia.com




Original Source Link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest News

Friend Who Blac Chyna Allegedly Assaulted Following Kardashian Trial Spills All – New Shady Details About Their Fight!

Blac Chyna‘s alleged attack on a friend — in which she reportedly kicked the woman in the stomach...

Google unveils new tools designed to fight skin color bias

Google announced a set of initiatives Wednesday aimed at creating a more equitable product experience for people across...

Alison Greenberg “Ruth Health”

Alison Greenberg is the CEO and Co-founder of “Ruth Health,” an innovative perinatal telehealth hub and comprehensive care platform...

Bitcoin Selloff Provides Boost To Miner Fee Revenues

Bitcoin sell-offs have been the order of the day since the weekend. This has translated to ever-decreasing prices...

High US inflation continues to cause concern

This article is an onsite version of our Disrupted Times newsletter. Sign up here to get the newsletter...

Must Read

Watching two sides of Europe unfold

This article is an on-site version of our...
- Advertisement -

You might also likeRELATED
Recommended to you